| (Values in U.S. Thousands) | Jun, 2025 | Jun, 2024 | Feb, 2026 | Feb, 2026 | Feb, 2026 |
| Sales | 2,350 | 200 | 0 | 0 | 0 |
| Sales Growth | +1,074.99% | unch | unch | unch | unch |
| Net Income | -24,830 | -31,450 | 0 | 0 | 0 |
| Net Income Growth | +21.05% | unch | unch | unch | unch |
Radiopharm Theranostics Limited ADR (RADX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Radiopharm Theranostic is a clinical-stage biopharmaceutical company focused on developing oncology radiopharmaceuticals for areas of high unmet medical need. Radiopharm Theranostic is based in SYDNEY.
Fiscal Year End Date: 06/30